While Shionogi & Co. Ltd. fell one short of its goal of progressing three drug candidates in fiscal 2018 (ending March 2019), the mid-sized Japanese pharma company is still hoping to take its launch tally globally to at least 10 compounds (including those out-licensed) by the end of the fiscal 2017-20 period.
"Our challenge for 2019 will be to focus on high-priority projects, and maximize the value of in-licensed projects," president and...







